Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Promimic

16.25 SEK

+2.20 %

Less than 1K followers

PRO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.20 %
+6.21 %
+6.91 %
-10.71 %
-27.78 %
-40.91 %
+39.25 %
-
-0.20 %

Promimic specializes in biotechnology. The company develops biocompatible surfaces for implants and conducts research in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The largest operations are in Europe and America, where research and development is conducted in-house but also through partners. Promimic is headquartered in Mölndal, Sweden.

Read more
Market cap
307M SEK
Turnover
14.57K SEK
Revenue
43.98M
EBIT %
-18.92 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24.2
2026

Annual report '25

19.5
2026

Interim report Q1'26

21.5
2026

General meeting '26

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.